Literature DB >> 28746941

Occurrence of Cranial Neoplasms in Pediatric Patients with Noonan Syndrome Receiving Growth Hormone: Is Screening with Brain MRI prior to Initiation of Growth Hormone Indicated?

Kanthi Bangalore Krishna1, Pedro Pagan2, Oscar Escobar2, Jadranka Popovic2.   

Abstract

Noonan syndrome (NS) is associated with short stature. Growth hormone treatment has been FDA approved for use in these patients. Children with NS are at a higher risk of developing benign and malignant proliferative disorders, primary brain tumors being one of them. Since growth hormone therapy can worsen the tumor burden, screening with a brain MRI prior to growth hormone initiation in NS patients is strongly recommended. Here we present two NS patients who developed different primary brain tumors while being on growth hormone therapy.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Brain tumors; Growth hormone; Noonan syndrome

Mesh:

Substances:

Year:  2017        PMID: 28746941      PMCID: PMC9204260          DOI: 10.1159/000479107

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   4.275


  8 in total

Review 1.  The oncogenic potential of growth hormone.

Authors:  Jo K Perry; B Starling Emerald; Hichem C Mertani; Peter E Lobie
Journal:  Growth Horm IGF Res       Date:  2006-11-13       Impact factor: 2.372

2.  Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database).

Authors:  Patrick Wilton; Anders F Mattsson; Feyza Darendeliler
Journal:  J Pediatr       Date:  2010-04-18       Impact factor: 4.406

Review 3.  Safety of growth hormone treatment in patients previously treated for cancer.

Authors:  Wassim Chemaitilly; Leslie L Robison
Journal:  Endocrinol Metab Clin North Am       Date:  2012-09-13       Impact factor: 4.741

4.  Pilocytic astrocytoma in a child with Noonan syndrome.

Authors:  Laura G Schuettpelz; Sharon McDonald; Kristina Whitesell; David M Desruisseau; Dorothy K Grange; Christina A Gurnett; David B Wilson
Journal:  Pediatr Blood Cancer       Date:  2009-12       Impact factor: 3.167

5.  Tumor development in three patients with Noonan syndrome.

Authors:  Helen Fryssira; George Leventopoulos; Stavroula Psoni; Sophia Kitsiou-Tzeli; Nikolaos Stavrianeas; Emmanuel Kanavakis
Journal:  Eur J Pediatr       Date:  2007-12-05       Impact factor: 3.183

Review 6.  Rosette forming glioneuronal tumor in association with Noonan syndrome: pathobiological implications.

Authors:  M Karafin; G I Jallo; M Ayars; C G Eberhart; F J Rodriguez
Journal:  Clin Neuropathol       Date:  2011 Nov-Dec       Impact factor: 1.368

7.  Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation.

Authors:  Marjolijn C J Jongmans; Ineke van der Burgt; Peter M Hoogerbrugge; Kees Noordam; Helger G Yntema; Willy M Nillesen; Roland P Kuiper; Marjolijn J L Ligtenberg; Ad Geurts van Kessel; J Han J M van Krieken; Lambertus A L M Kiemeney; Nicoline Hoogerbrugge
Journal:  Eur J Hum Genet       Date:  2011-03-16       Impact factor: 4.246

Review 8.  Noonan syndrome.

Authors:  Ineke van der Burgt
Journal:  Orphanet J Rare Dis       Date:  2007-01-14       Impact factor: 4.123

  8 in total
  2 in total

Review 1.  Inside the Noonan "universe": Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns.

Authors:  Stefano Stagi; Vittorio Ferrari; Marta Ferrari; Manuela Priolo; Marco Tartaglia
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-18       Impact factor: 6.055

2.  Effect of Growth Hormone Therapy in Patients with Noonan Syndrome: A Retrospective Study.

Authors:  Louise Jayne Apperley; Renuka Ramakrishnan; Poonam Dharmaraj; Urmi Das; Mohammed Didi; Jo Blair; Senthil Senniappan
Journal:  Int J Endocrinol Metab       Date:  2020-10-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.